Imprivata (IMPR) Tops Q4 EPS by 1c, Offers Q1 & FY Guidance

Imprivata (NYSE: IMPR) reported Q4 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $34.2 million versus the consensus estimate of $33.15 million.

GUIDANCE:

Imprivata sees Q1 2016 EPS of ($0.36)-($0.32), versus the consensus of ($0.21). Imprivata sees Q1 2016 revenue of $28-30 million, versus the consensus of $29.60 million.

Imprivata sees FY2016 EPS of ($0.63)-($0.58), versus the consensus of ($0.39). Imprivata sees FY2016 revenue of $136-140 million, versus the consensus of $141.34 million.

For earnings history and earnings-related data on Imprivata (IMPR) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Tenon Medical (TNON) Misses Q2 EPS by 395c